Page 7 of 7
Are there plans for further studies?
In addition to the two parts of this study, no other studies of otilimab in participants
with COVID-19 related lung disease are planned or ongoing at this time. Otilimab
continues to be studied for the treatment of other diseases, such as rheumatoid
arthritis.
Where can I find more information about this study?
Clinical studies have unique study numbers that are included in publications and other
information about the study. The unique study numbers associated with this study are
shown below with internet links to scientific summaries.
The scientific summaries include more details about the requirements for study
enrolment, the study visit schedule, results from other endpoints, and more detailed
information about adverse events.
Organisation and Website Study Number
European Medicines Agency
2020-001759-421
(www.clinicaltrialsregister.eu)
United States National Institutes of Health (NIH)
NCT043766842
(www.clinicaltrials.gov)
Your doctor can help you understand more about this study and the results. Speak to
your doctor about the treatment options available in your country. You should not
make changes to your care based on the results of this or any single study. Keep taking
your current treatment unless instructed by your doctor.
We would like to thank the participants who contributed to this study. The results of
this study will help answer scientific questions about treating patients with COVID-19
related lung disease.
The content for this document was finalised by GSK on 23 February 2022. The
information in this summary does not include additional information available after this
date.
1https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-001759-42
2https://clinicaltrials.gov/ct2/show/NCT04376684